N-linoleyltyrosine

Networked: 3 relevant articles (1 outcomes, 0 trials/studies)

1.	Obesity 01/01/2022 - "N-linoleyltyrosine ameliorates high-fat diet-induced obesity in C57BL/6 mice via cannabinoid receptor regulation."
2.	Neoplasms (Cancer) 01/01/2023 - "Background: N-linoleyltyrosine (NITyr), one of the anandamide analogs, exerts activity via the endocannabinoid receptors (CB1 and CB2), which showed anti-tumor effects in various tumors. "
3.	Transient Ischemic Attack 11/01/2019 - "N-Linoleyltyrosine Protects against Transient Cerebral Ischemia in Gerbil via CB2 Receptor Involvement in PI3K/Akt Signaling Pathway."
4.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/01/2023 - "N-linoleyltyrosine resisted the growth of non-small cell lung cancer cells via the regulation of CB1 and CB2 involvement of PI3K and ERK pathways."

1.	Cannabinoid Receptors (Cannabinoid Receptor)
2.	Endocannabinoids
3.	CB2 Cannabinoid Receptor
4.	anandamide (arachidonylethanolamide)